Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H2 2016, provides an overview of the Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) pipeline landscape. Methicillin-Susceptible Staphylococcus aureus (MSSA) is a bacterium that is resistant to many antibiotics. MSSA usually cause skin infections, but can also cause pneumonia, and other serious types of infections. Symptoms include cellulitis, painful rashes, nausea and vomiting, fever, muscle aches, diarrhea and abdominal pain. Predisposing factors include weakened immune systems, burns and surgical wounds. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections. Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Overview 6 Therapeutics Development 7 Pipeline Products for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Overview 7 Pipeline Products for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Comparative Analysis 8 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics under Development by Companies 9 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics under Investigation by Universities/Institutes 10 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Products under Development by Companies 13 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Products under Investigation by Universities/Institutes 14 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Companies Involved in Therapeutics Development 15 Arsanis, Inc. 15 ContraFect Corporation 16 Debiopharm International SA 17 Sealife PHARMA GMBH 18 Sumitomo Dainippon Pharma Co Ltd 19 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 ASN-100 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 CF-301 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 Debio-1450 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 NAI-108 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 SLP-0904 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 SLP-0905 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 SM-295291 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 SM-369926 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Small Molecules for Bacterial Infections - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Synthetic Peptide for Oncology and Infectious Disease - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 targocil - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects 44 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products 45 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Product Development Milestones 46 Featured News & Press Releases 46 Dec 02, 2014: ContraFect Submits Complete Response to IND Clinical Hold for CF-301 46 Appendix 47 Methodology 47 Coverage 47 Secondary Research 47 Primary Research 47 Expert Panel Validation 47 Contact Us 47 Disclaimer 48
List of Tables Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, H2 2016 7 Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Number of Products under Investigation by Universities/Institutes, H2 2016 10 Comparative Analysis by Clinical Stage Development, H2 2016 11 Comparative Analysis by Early Stage Development, H2 2016 12 Products under Development by Companies, H2 2016 13 Products under Investigation by Universities/Institutes, H2 2016 14 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Arsanis, Inc., H2 2016 15 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by ContraFect Corporation, H2 2016 16 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Debiopharm International SA , H2 2016 17 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Sealife PHARMA GMBH, H2 2016 18 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 19 Assessment by Monotherapy Products, H2 2016 20 Number of Products by Stage and Target, H2 2016 22 Number of Products by Stage and Mechanism of Action, H2 2016 24 Number of Products by Stage and Route of Administration, H2 2016 26 Number of Products by Stage and Molecule Type, H2 2016 28 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects, H2 2016 44 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products, H2 2016 45
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.